ALAWAY (ketotifen fumarate) by Bausch + Lomb is state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake). Approved for allergic conjunctivitis, seasonal allergic conjunctivitis. First approved in 2006.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
ALAWAY is a ketotifen fumarate ophthalmic solution approved in 2006 for allergic and seasonal allergic conjunctivitis. It functions as an H1 receptor antagonist and mast cell stabilizer that prevents ocular allergic itch for up to 12 hours, enabling continued lens wear during allergen exposure. The drug is administered as topical eye drops.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive positioning and team focus on managed care and physician retention strategies.
state, the lens when placed on the cornea, acts as a refracting medium to focus light rays on the retina to correct refractive ametropia for as long as the lens is worn (up to 24 hours while awake). Drug Component Ketotifen fumarate, a benzocycloheptathiophene derivative, is a H 1 receptor…
Worked on ALAWAY at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
ALAWAY offers limited career growth opportunity given its LOE-approaching lifecycle and zero linked job postings; roles are predominantly defensive, focused on market share retention and managed care negotiation rather than launch momentum. Career value lies in mature commercial execution, managed care expertise, and strategic positioning ahead of generic entry.